167 related articles for article (PubMed ID: 38388871)
1. Etrasimod: First Approval.
Shirley M
Drugs; 2024 Feb; 84(2):247-254. PubMed ID: 38388871
[TBL] [Abstract][Full Text] [Related]
2. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ; Vermeire S; Peyrin-Biroulet L; Dubinsky MC; Panes J; Yarur A; Ritter T; Baert F; Schreiber S; Sloan S; Cataldi F; Shan K; Rabbat CJ; Chiorean M; Wolf DC; Sands BE; D'Haens G; Danese S; Goetsch M; Feagan BG
Lancet; 2023 Apr; 401(10383):1159-1171. PubMed ID: 36871574
[TBL] [Abstract][Full Text] [Related]
3. The Selective Sphingosine 1-Phosphate Receptor Modulator Etrasimod Regulates Lymphocyte Trafficking and Alleviates Experimental Colitis.
Al-Shamma H; Lehmann-Bruinsma K; Carroll C; Solomon M; Komori HK; Peyrin-Biroulet L; Adams J
J Pharmacol Exp Ther; 2019 Jun; 369(3):311-317. PubMed ID: 30872391
[TBL] [Abstract][Full Text] [Related]
4. Etrasimod for the treatment of ulcerative colitis.
Wils P; Peyrin-Biroulet L
Immunotherapy; 2023 Apr; 15(5):311-321. PubMed ID: 36789612
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
Sandborn WJ; Peyrin-Biroulet L; Zhang J; Chiorean M; Vermeire S; Lee SD; Kühbacher T; Yacyshyn B; Cabell CH; Naik SU; Klassen P; Panés J
Gastroenterology; 2020 Feb; 158(3):550-561. PubMed ID: 31711921
[TBL] [Abstract][Full Text] [Related]
6. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
[TBL] [Abstract][Full Text] [Related]
7. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study.
Vermeire S; Chiorean M; Panés J; Peyrin-Biroulet L; Zhang J; Sands BE; Lazin K; Klassen P; Naik SU; Cabell CH; Sandborn WJ
J Crohns Colitis; 2021 Jun; 15(6):950-959. PubMed ID: 33475734
[TBL] [Abstract][Full Text] [Related]
8. Modulation of sphingosine-1-phosphate in ulcerative colitis.
Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
[No Abstract] [Full Text] [Related]
9. Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis.
Choi D; Becker M; Ivanov M; Bhat S
Ann Pharmacother; 2024 Jan; ():10600280231225770. PubMed ID: 38258760
[TBL] [Abstract][Full Text] [Related]
10. Ritlecitinib: First Approval.
Blair HA
Drugs; 2023 Sep; 83(14):1315-1321. PubMed ID: 37556041
[TBL] [Abstract][Full Text] [Related]
11. Mirikizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1045-1052. PubMed ID: 37389706
[TBL] [Abstract][Full Text] [Related]
12. Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
Yarur AJ; Chiorean MV; Panés J; Jairath V; Zhang J; Rabbat CJ; Sandborn WJ; Vermeire S; Peyrin-Biroulet L
J Crohns Colitis; 2024 Jan; ():. PubMed ID: 38245818
[TBL] [Abstract][Full Text] [Related]
13. In moderately to severely active UC, etrasimod increased remission at 12 and 52 wk but increased adverse events.
Al-Jabri R; Afif W
Ann Intern Med; 2023 Jul; 176(7):JC82. PubMed ID: 37399559
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis.
Bencardino S; D'Amico F; Faggiani I; Bernardi F; Allocca M; Furfaro F; Parigi TL; Zilli A; Fiorino G; Peyrin-Biroulet L; Danese S
J Clin Med; 2023 Jul; 12(15):. PubMed ID: 37568417
[TBL] [Abstract][Full Text] [Related]
15. Ozanimod: A Review in Ulcerative Colitis.
Paik J
Drugs; 2022 Aug; 82(12):1303-1313. PubMed ID: 35994200
[TBL] [Abstract][Full Text] [Related]
16. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE).
Silverberg JI; Bissonnette R; Kircik L; Murrell DF; Selfridge A; Liu K; Ahluwalia G; Guttman-Yassky E
J Eur Acad Dermatol Venereol; 2023 Jul; 37(7):1366-1374. PubMed ID: 36695074
[TBL] [Abstract][Full Text] [Related]
18. Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
Regueiro M; Siegmund B; Yarur AJ; Steinwurz F; Gecse KB; Goetsch M; Bhattacharjee A; Wu J; Green J; McDonnell A; Crosby C; Lazin K; Branquinho D; Modesto I; Abreu MT
J Crohns Colitis; 2024 May; ():. PubMed ID: 38700040
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
Peyrin-Biroulet L; Dubinsky MC; Sands BE; Panés J; Schreiber S; Reinisch W; Feagan BG; Danese S; Yarur AJ; D'Haens GR; Goetsch M; Wosik K; Keating M; Lazin K; Wu J; Modesto I; McDonnell A; Bartolome L; Vermeire S
J Crohns Colitis; 2024 Apr; ():. PubMed ID: 38613425
[TBL] [Abstract][Full Text] [Related]
20. The sphingosine-1-phosphate receptor agonist etrasimod in ulcerative colitis.
Atreya R; Neurath MF
Lancet; 2023 Apr; 401(10383):1132-1133. PubMed ID: 36871570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
